Search clinical trials for: AZD1704

Total 100 results

AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704

Pain

United Kingdom
AstraZeneca

Terminated

Assess Safety, Tolerability and Pharmacokinetic (PK) of AZD1704 in Healthy Japanese Male and Non-Fertile Female Volunteers

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Evaluate Different Extended-release (ER) Tablets/Capsules of AZD1305 (2007-005765-38)

Healthy

United Kingdom
Ardelyx

Completed

AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study

Healthy Volunteers

United Kingdom
AstraZeneca

Recruiting

Study of AZD0754 in Participants With Metastatic Prostate Cancer (APOLLO)

Metastatic Prostate Cancer

United States, Australia
AstraZeneca

Completed

Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

Advanced Solid Malignancies | Malignant Lymphoma

United Kingdom, Japan
AstraZeneca

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients

Acute Myeloid Leukemia

United States, Canada
AstraZeneca

Completed

Cardiac Electrophysiological Study

Atrial Flutter

Finland, Norway, Denmark, Sweden
AstraZeneca

Completed

Study to Assess Drug Concentrations in Plasma of Different Extended-release Formulations of AZD1305

Healthy

United Kingdom
Ardelyx

Completed

Dose Finding Study to Treat High Phosphate Levels in the Blood.

Hyperphosphatemia

United States, Poland, United Kingdom, Slovakia
AstraZeneca

Completed

Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305

Atrial Fibrillation

Sweden, Czech Republic, Hungary, Poland, Netherlands, Norway, Denmark, Slovakia
AstraZeneca

Completed

Explorative Study of AZD1305 in Atrial Fibrillation Patients

Atrial Fibrillation

Russian Federation, Poland, Denmark, Norway, Slovakia, Sweden
AstraZeneca

Completed

A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma

Asthma

United Kingdom
AstraZeneca

Not yet recruiting

LTFU for All Cell and Gene Therapy Studies (LOCUS)

Hepatocellular Carcinoma | Prostate Cancer

United States
Ardelyx
AstraZeneca

Completed

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States
AstraZeneca

Completed

Study of an Extended Release (ER) Tablet, Single and Repeated Dosing

Healthy

Sweden
AstraZeneca

Terminated

Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients

Type 2 Diabetes

Sweden
AstraZeneca

Terminated

AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects (JMAD)

Healthy

United States
AstraZeneca
Parexel

Not yet recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Cardiovascular

United States
Ardelyx
AstraZeneca

Completed

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

End Stage Renal Disease | ESRD | Chronic Kidney Disease Stage 5

United States
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Cardiovascular

United States
Ardelyx

Completed

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C (T3MPO-3)

Constipation Predominant Irritable Bowel Syndrome

United States
AstraZeneca
Quotient Sciences

Active, not recruiting

An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604

Asthma

United Kingdom
Inflazome UK Ltd

Withdrawn

PK Study in Patients With Parkinson's Disease With IZD174

Parkinson Disease
Ardelyx

Completed

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C (T3MPO-2)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

Healthy Volunteer

United States
Ardelyx

Completed

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C (T3MPO-1)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Healthy
Ardelyx

Completed

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

Hyperphosphatemia

United States
Ardelyx

Completed

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

Healthy Volunteers Food Interaction Study

United States
AstraZeneca

Recruiting

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA (AJAX)

Asthma

Denmark, United States, United Kingdom, Argentina, Vietnam, Brazil, Malaysia, France, Germany, Spain, Taiwan, Thailand, Bulgaria, Philippines, South Africa, Sweden
AstraZeneca

Completed

To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305

Healthy

United Kingdom
AstraZeneca

Completed

To Study Safety, Tolerability and Pharmacokinetics of AZD1305 in Healthy Male Japanese Subjects

Healthy

Japan
AstraZeneca

Completed

Single Ascending Dose Study (SAD) iv Formulation (2006-006253-27)

Healthy

Sweden
AstraZeneca

Completed

Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction

Left Ventricle Function

Sweden
NYU Langone Health

Terminated

AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibroses

United States
AstraZeneca
Parexel

Terminated

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects

Healthy Subjects (Indication: Asthma)

United Kingdom
AstraZeneca

Completed

Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402

Asthma

United Kingdom
Ardelyx

Completed

Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Healthy
AstraZeneca

Active, not recruiting

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Melanoma | Cervical Cancer | Small Cell Lung Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumours | Non-Small-Cell Lung Cancer | Gastroesophageal Cancer | Clear Cell Renal Cell Cancer | Squamous Cell Cancer of Head and Neck

United States, Spain, Canada, France
AstraZeneca

Terminated

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Previously Treated Non Small Cell Lung Cancer

United States
AstraZeneca

Completed

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Ovarian Cancer | Locally Advanced Solid Tumours | Metastatic Solid Tumours

United States
AstraZeneca
Parexel

Terminated

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Advanced Solid Tumours

United Kingdom, United States
Samsung Medical Center

Completed

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients

Small Cell Lung Cancer

Korea, Republic of
AstraZeneca
Parexel

Completed

A Study of Adavosertib as Treatment for Uterine Serous Carcinoma (ADAGIO)

Uterine Serous Carcinoma

United States, Italy, Spain, France, Canada
Samsung Medical Center

Terminated

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation

Small Cell Lung Cancer

Korea, Republic of
Dana-Farber Cancer Institute
AstraZeneca

Active, not recruiting

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Uterine Cancer

United States
AstraZeneca
Quintiles, Inc.

Completed

Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours

Solid Tumours

France, United Kingdom, Netherlands
AstraZeneca

Terminated

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer

United States

3

Subscribe